• Link to X
  • Hi,
  • Member Dashboard
  • Log Out
  • Contact
Grasp Cancer
  • About
    • What We Do
    • For Researchers
    • For Advocates
    • Our Team
    • Board of Advisors
    • Careers
  • Join Us
  • Events
  • News
  • Login
  • Donate
  • Menu Menu
  • About
    • What We Do
    • For Advocates
    • For Researchers
    • Our Team
    • Board of Advisors
    • Careers
  • Events
  • Join Us
  • News
  • Contact
  • Member Dashboard (Old)
  • Log In
  • Log Out
  • Donate

Group 5E: HER2-negative Metastatic Breast Cancer; Brain Metastasis; Leptomeningeal Disease

Group 5D: HER2+ Locally Advanced and Metastatic Breast Cancer; Antibody-drug Conjugates; Treatment Resistance

Group 5C: Metastatic Breast Cancer; Antibody-drug Conjugates; Treatment Response and Resistance

Group 5B: Metastatic Breast Cancer; Symptom Management; Dosing Strategies

Group 5A: Lobular Breast Cancer; Risk Prediction

Group 4E: HR+ Locally Advanced and Metastatic Breast Cancer; PIK3CA Mutations; Treatment Resistance

Group 4D: Triple Negative Locally Advanced and Metastatic Breast Cancer; Antibody-drug Conjugates; Immunotherapy

Group 4C: Metastatic Breast Cancer; Antibody-drug Conjugates; Treatment Response and Resistance

Group 4B: Metastatic Breast Cancer; Bone Metastasis

Group 4A: HER2+ and HER2-low Metastatic Breast Cancer; Antibody-drug Conjugates; Treatment Resistance

Page 1 of 3123

GUIDING RESEARCHERS & ADVOCATES TO SCIENTIFIC PARTNERSHIPS

  • What We Do
  • For Researchers
  • For Advocates
  • Our Team
  • Board of Advisors
  • Careers
  • Donate
@2020 Grasp Cancer | All rights reserved. | Site by Dot Think
  • Link to X
Scroll to top Scroll to top Scroll to top